Respicardia reels in $6M for heart failure/apnea implantable device

Minnesota startup Respicardia secured $6 million in debt financing to advance clinical trial work for a unique implantable device. As the Minneapolis/St. Paul Business Journal reports, the treatment is targeted toward heart failure patients who also experience central sleep apnea, where patients stop breathing briefly through the night. Ares Capital supplied the funding. Story (sub. req.)

Suggested Articles

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.